Thyrocare Technologies
Market cap ₹8,025 Cr
- P/E
- 55.83
- Day range
- ₹502.95 – ₹519.85
- 52-week range
- ₹342.55 – ₹662.00
- Volume
- 2.05 L
- Open
- ₹506.00
- Prev close
- ₹506.95
Latest results · Q2 FY27(consolidated)Revenue ₹271 Cr+25.1%Profit ₹15 Cr-68.2%Margin 5.6%YoY vs the same quarter last year
1 red flag to read up on
- medium
Promoter holding falling
51.02%, down 9.91 pts since 2025-12-01 · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
THYROCARE in NSE indices and F&O
Research profile
Composite 56 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.8%
- Graham no.
- ₹92.39
- vs Graham
- -81.7%
- ROE ÷ P/B
- 2.0%
- 12-1 mom.
- +7.3%
- Return / vol
- 0.28
- Magic Formula
- #238
- Piotroski
- 5/6
- FCF yield
- 2.4%
Appears in 7 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Thyrocare TechnologiesTHYROCARE | ₹8,025 Cr | 55.83 | 14.57 | 28.8% | 35.0% | 33.0% | 0.10 | +24.9% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 5h agoHeadlines about Thyrocare Technologies from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 46.2
- Price / Book
- 14.47
- ROE (FY26)
- 28.8%
- ROCE (latest year)
- 35%
- Dividend yield
- 1.84%
Moving averages (NSE)
- 20-day
- ₹487.05
- Price above
- 50-day
- ₹517.84
- Price below
- 200-day
- ₹488.72
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- Public
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 28 Nov 2025: earlier bars are per pre-bonus share.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 135 | 154 | 157 | 177 | 166 | 187 | 193 | 217 | 196 | 224 | 240 | 271 |
| Expenses | 103 | 121 | 115 | 129 | 124 | 130 | 135 | 145 | 138 | 149 | 163 | 182 |
| Operating Profit | 32 | 34 | 42 | 48 | 42 | 57 | 58 | 71 | 58 | 75 | 77 | 89 |
| OPM % | 23% | 22% | 27% | 27% | 25% | 30% | 30% | 33% | 30% | 34% | 32% | 33% |
| Other Income | 3 | 3 | 4 | 3 | 4 | 5 | 5 | 3 | -1 | 5 | 5 | -41 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | 2 |
| Depreciation | 13 | 13 | 11 | 13 | 17 | 14 | 11 | 12 | 22 | 14 | 12 | 14 |
| Profit before tax | 20 | 23 | 34 | 37 | 28 | 47 | 50 | 63 | 35 | 64 | 68 | 34 |
| Tax % | 26% | 25% | 29% | 28% | 32% | 54% | 24% | 24% | 21% | 24% | 25% | 55% |
| Net Profit | 15 | 17 | 24 | 26 | 19 | 22 | 38 | 48 | 28 | 49 | 51 | 15 |
| EPS in Rs | ₹0.97 | ₹1.12 | ₹1.52 | ₹1.68 | ₹1.20 | ₹1.36 | ₹2.45 | ₹3.02 | ₹1.82 | ₹2.96 | ₹3.28 | ₹1.00 |
From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
0 days since Mar 2021
+29 days since Mar 2021
+53 days since Mar 2021
-25 days since Mar 2021
0 days since Mar 2021
Strengths, risks & growth
Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.
Strengths
- Company has been maintaining a healthy dividend payout of 131%
Risks
- Stock is trading at 14.6 times its book value
- Promoter holding has decreased over last quarter: -9.90%
Compounded Sales Growth
- 10 Years
- +13%
- 5 Years
- +11%
- 3 Years
- +16%
- TTM
- +22%
Compounded Profit Growth
- 10 Years
- +12%
- 5 Years
- +8%
- 3 Years
- +36%
- TTM
- +37%
Stock Price CAGR
- 10 Years
- +10%
- 5 Years
- +5%
- 3 Years
- +42%
- 1 Year
- -2%
Return on Equity
- 10 Years
- +21%
- 5 Years
- +20%
- 3 Years
- +20%
- Last Year
- +28%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 60.93% | 60.92% | 60.92% | 51.02% | -9.90 pp |
| FII | 4.96% | 5.37% | 5.43% | 9.37% | +3.94 pp |
| DII | 20.52% | 21.00% | 20.92% | 25.92% | +5.00 pp |
| Public | 13.61% | 12.71% | 12.71% | 13.69% | +0.98 pp |
Filed with NSE for Sept 2026: promoters 51.02%, public 48.98%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 22.91% (+3.05 pp)- Promoters51.0%
- Foreign institutions9.4%
- Mutual funds22.9%
- Insurance1.9%
- Other domestic institutions1.1%
- Retail9.0%
- Others4.7%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HSBC Midcap Fund | 3.20% | 1.54% | -0.09 pp |
| Nippon India Small Cap Fund | 2.92% | 0.31% | -0.07 pp |
| Aditya Birla SL ELSS Tax Saver Fund | 2.40% | 1.43% | +0.11 pp |
| Nippon India Pharma Fund | 2.19% | 1.93% | -0.58 pp |
| ICICI Pru Dividend Yield Fund | 1.39% | 1.79% | -0.04 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026. Adjusted for 1 corporate action.
Risk
- Volatility (1Y)
- 41.1%
- Downside volatility
- 39.5%
- Worst 5% of days
- 4.0%
- Average of that tail
- 5.8%
- Max drawdown (1Y)
- 34.1%
- Below its peak
- 22.4%
Against the market
- Beta vs Nifty 50
- 0.50
- Correlation
- 0.17
- Relative strength (3M)
- -22.5%
- ATR (14)
- 4.0%
Return
- Return 1M
- +3.8%
- Return 3M
- -18.6%
- Return 6M
- +11.4%
- Return 1Y
- +11.4%
- vs 200-day average
- +3.0%
Momentum
- RSI (14)
- 51.5
- MACD histogram
- 5.09
- Stochastic %K
- 77.5
- ADX (14)
- 18.2
- +DI / −DI
- 21.8 / 22.7
- Money flow index
- 28.5
Participation
- Delivery (20d avg)
- 49.3%
- vs its 60-day baseline
- -4.3 pts
- Volume vs 20-day
- -0.4σ
- Close vs day's VWAP
- -1.0%
- 52-week position
- 51 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
5 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — passed
- Free cash flow
- ₹192 Cr
- FCF yield
- 2.4%
- Cash conversion
- 1.31
- Accruals ratio
- -0.067
- Net debt
- ₹35 Cr
- Net debt / equity
- 0.06
- EV / sales
- 8.72
- Capex intensity
- 2.5%
- Revenue CAGR
- 27.9%
- Profit CAGR
- -20.7%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Rahul Guha Designated Person · Market Purchase | Buy | 2,121 | ₹10.4 L | 7 Nov 2026 |
Priyanka Jagnani Jain Immediate Relative · Market Purchase | Buy | 2,006 | ₹9.0 L | 4 Nov 2026 |
Brijesh Kumar KMP · Market Purchase | Buy | 330 | ₹1.5 L | 4 Nov 2026 |
Docon Technologies Private Limited Promoter · Pledge Release | Pledge | 7,94,69,696 | ₹4916 Cr | 18 Aug 2026 |
Docon Technologies Private Limited Promoter · Pledge Release | Pledge | 1,75,00,000 | ₹1089 Cr | 13 Aug 2026 |
Docon Technologies Private Limited Promoter · Block Deal | Sell | 1,31,68,657 | ₹815 Cr | 13 Aug 2026 |
Docon Technologies Private Limited Promoter · Market Sale | Sell | 26,01,039 | ₹163 Cr | 13 Aug 2026 |
Mohammad Shadab Alam Designated Person · Market Sale | Sell | 100 | ₹59,850 | 7 Aug 2026 |
Priyanka Jagnani Jain Market Purchase | Buy | 2,500 | ₹8.8 L | 1 Apr 2026 |
Geetanjali Satish Shahane Market Purchase | Buy | 1,000 | ₹3.6 L | 1 Apr 2026 |
Rahul Guha Market Purchase | Buy | 10,000 | ₹36.6 L | 20 Mar 2026 |
Piyush Singh Market Purchase | Buy | 400 | ₹1.5 L | 20 Mar 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹7.00
Dividend - Rs 7 Per Share
23 Jun 2026ex-date - bonusNot available — not reported in this filing
Bonus 2:1
28 Nov 2025ex-date - dividend₹7.00
Interim Dividend - Rs 7 Per Share
24 Oct 2025ex-date - dividend₹21.00
Dividend - Rs 21 Per Share
25 Jul 2025ex-date - dividend₹18.00
Dividend - Rs 18 Per Share
16 Aug 2024ex-date - dividend₹18.00
Interim Dividend - Rs 18 Per Share
20 Apr 2023ex-date - otherNot available — not reported in this filing
Annual General Meeting
25 Jul 2022ex-date - dividend₹15.00
Interim Dividend - Rs 15 Per Share
11 May 2022ex-date - dividend₹15.00
Annual General Meeting/Dividend - Rs 15 Per Share
17 Jun 2021ex-date - dividend₹10.00
Interim Dividend - Rs 10 Per Share
12 Nov 2020ex-date - dividend₹5.00
Interim Dividend - Rs 5 Per Share
21 Nov 2019ex-date - dividend₹20.00
Dividend - Rs 20 Per Share
14 Aug 2019ex-date - dividend₹5.00
Annual General Meeting/Dividend- Rs 5 Per Share
2 Aug 2018ex-date - dividend₹5.00
Interim Dividend Rs 5/- Per Share
15 Feb 2018ex-date - dividend₹5.00
Annual General Meeting/Dividend - Rs 5/- Per Share
3 Aug 2017ex-date - dividend₹5.00
Interim Dividend Rs 5/- Per Share (Purpose Revised)
8 Feb 2017ex-date - dividend₹2.50
Annual General Meeting/Dividend - Rs 2.50 Per Share
1 Sept 2016ex-date
Company announcements
Please find attached herewith Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026
Please find attached the Copies of Newspaper Publications for Notice of Postal Ballot
Please find attached herewith Notice of Postal Ballot dated September 21, 2026
Please find attached herewith Intimation relating Grant of Options under Thyrocare Employee Stock Option Scheme
Please find attached the Intimation for Closure of Trading Window
Please find attached Intimation Letter
Please find attached intimation regarding Acquisition of Compulsorily Convertible Preference Shares of Trovera Healthcare Private Limited as part-consideration for the sale of Nueclear ....
Outcome of the Board meeting held on Monday, September 21, 2026
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 08, 2026 for Docon Technologies ....
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for API Holdings Ltd
Please find enclosed herewith copies of Newspaper Publications published on September 04, 2026 in Business Standard (English) and Lakshadeep (Marathi)
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for API Holdings Ltd
Please find enclosed the Intimation regarding approval of Scheme of Amalgamation of Docon Technologies Private Limited with API Holdings Limited
Please find enclosed the Intimation regarding complete discharge and release of Transaction Documents pursuant to full redemption and repayment of Non-Convertible Debentures by API Holdings Limited
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
Filed with BSE (scrip 539871); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Buybacks, open offers & rights issues
- Open offer
Thyrocare Technologies Limited
28 Jun 2021Read on SEBI - Buyback - Public Announcement
Thyrocare Technologies Limited - Public Announcement
17 Sept 2018Read on SEBI
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Jul 2026TranscriptSlidesRecording
- May 2026TranscriptSlides
- Feb 2026TranscriptSlidesRecording
- Oct 2025TranscriptSlides
- Jul 2025TranscriptSlidesRecording
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 30 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Thyrocare Technologies: common questions
Answered from the figures on this page.